Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
Times cited: 58
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Journal of Clinical Oncology.
Times cited: 344
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.
Clinical Cancer Research.
Times cited: 274